Differences in Gastric Microbiota in Patients Who Were Infected Between CagA Positive and Negative Helicobacter Pylori
Launched by MAHIDOL UNIVERSITY · Jan 20, 2025
Trial Information
Current as of July 22, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients aged over 18 with an indication for EGD
- • Helicobacter pylori infection (Rapid urease test positive)
- Exclusion Criteria:
- • Severe comorbidities: poorly controlled DM, ESRD, decompensated cirrhosis, Malignancy
- • BMI ≤ 23 kg/m2
- • Receiving medications that affect the gastric microbiota include Antibiotics, probiotics, or bismuth within 4 weeks, PPI within 2 weeks, NSAIDs or Metformin within 2 weeks
- • History of cholecystectomy or proximal small bowel surgery
About Mahidol University
Mahidol University, a premier institution in Thailand, is dedicated to advancing healthcare through innovative research and education. As a leading sponsor of clinical trials, the university leverages its extensive expertise in medical and health sciences to facilitate rigorous scientific investigations aimed at improving patient care and public health outcomes. With a commitment to ethical practices and collaboration, Mahidol University fosters multidisciplinary approaches, engaging a diverse array of researchers and healthcare professionals to drive meaningful advancements in clinical research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bangkok Noi, Bangkok, Thailand
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported